Tag Archives: LF

Letter to a Parasite

By: Amanda Miller

Dear Lymphatic Filariasis,

You disgust me.  You are a parasite.  You use unsuspecting mosquitoes to spread thread-like worms into unsuspecting humans.  You occupy the lymphatic system in humans, and in severe cases, you lead to elephantiasis.  In case you didn’t know, that’s massive and painful swelling of limbs.  You cause pain, immobility, and problems for human beings that happen to be mothers, brothers, bread-winners, fathers, teachers, workers, sisters, cousins, friends.  You’ve never bothered to ask for permission or wondered how your parasitic existence would affect their lives.  To be honest, I’m pretty angry about this.

In fact, we use your name -parasite- to mean something so self-serving that would attach itself to someone else and live off of their life.  Yes, we may have referred to past partners, boyfriends and girlfriends as parasites (evidently, relationships that don’t work out).  We use your name for unsolicited malicious computer programs that destroy our hard drives.  We use your name to talk about things that disgust us.  Yes, we humans love a good analogy.

Continue reading

Ending the neglect

UK-based journalist Emilie Filou (who recently authored this great article on Trachoma), writes about neglected tropical diseases again for This is Africa. The article also features snippets from interviews Filou conducted with Dr. Neeraj Mistry, Managing Director of the Global Network, and Dr. Peter Hotez. The piece discusses the role of pharmaceuticals in NTD control, the importance of integration across other disease and issue areas and elimination goals.

From the article:

“The term ‘other disease’ has been a great frustration,” says Dr Peter Hotez, president of the Sabin Vaccine Institute and an expert on NTDs. “It’s quite clear that you won’t get Bono or Angelina Jolie to help out with ‘other diseases’. That’s what spurred us to call them Neglected Tropical Diseases as a group. It’s not the greatest of names, but it will help galvanise awareness,” he says.

Advocacy group The Global Network for NTDs is now lobbying to include NTDs under the remit of The Global Fund, Pepfar or the President’s Malaria Initiative. “We have new data coming out of Zimbabwe that shows that women infected with schistosomiasis are three times more likely to be infected with HIV,” explains Dr Neeraj Mistry, managing director of the Global Network.

“Treating schistosomiasis therefore becomes an intervention for HIV control; it’s those links we need to make to justify the inclusion of NTDs in global health efforts.”

There are many more such synergies: HIV-positive individuals have seen a decrease in their viral load when de-wormed; lymphatic filariasis is transmitted by mosquitoes, so the use of bednets, widely distributed for malaria control, is an efficient prevention measure.

Dr Mistry says that including NTDs in the Global Fund would only increase their budget marginally, but substantially increase their impact. “It costs as little $0.5 per year to treat an individual against NTDs. Compare that with the $100 it costs to treat someone with HIV, or the $35 the average African family spends on malaria control. In terms of investment, you won’t find a better return in health.”

To read the full article click here

Footage from the 6th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis

As we mentioned, the 6th Meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) met from June 1 – June 3, 2010 and focused on developing strategies for lymphatic filariasis (LF) elimination for the next 10 years. Working with public and private partners, GAELF mobilizes political, financial, and technical resources to achieve LF elimination. Within this past decade, The Global Program has already established interventions to address LF in 51 of the 80 endemic countries. The 6th meeting held this past June focused on new strategies for elimination for the next decade. GAELF recently posted footage from the three day meeting, which can be viewed here.

Elimination of lymphatic filariasis: do we have the drugs to complete the job?

2020 is the deadline that the WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF) set to eliminate lymphatic filariasis (LF). Currently LF is treated through mass drug administration (MDA) – which is administering drugs to an entire population to treat a diseases –  using diethylcarbamazine or ivermectin monotherapy, or either drug in combination with albendazole. However, over the past five years of MDA, transmission of LF has yet to be interrupted. Other issues that have arisen include development of adverse health effects (specifically the onset of Loa loa) associated with consumption of the current drugs used for treatment. Moses J. Bockarie and Rinki M. Deb of the Liverpool School of Tropical Medicine recently published an article reviewing the current state of LF elimination. Read the full article here.